Lymph Node Regression Improves Prognostic Stratification in Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Cohort Study
Authors:
Open Access
Abstract
Lymph nodes (LNs), principal sites of antitumor immunity, may undergo immune‐mediated regression; whether neoadjuvant chemoimmunotherapy (NCIT)‐induced regression indicates prognosis in esophageal squamous cell carcinoma (ESCC) remains unclear. We aimed to establish and validate a lymph node regression grade (LNRG) system for prognostic stratification. This multicenter, retrospective cohort study analyzed 965 patients receiving PD‐1‐based NCIT and surgery at three Chinese tertiary cancer centers. LNRG was the ratio of summed viable tumor area to summed bed area (residual viable plus regressed preexisting tumor) across all dissected LNs. Negative LNs were assigned LNRG 0. Survival and predictive performance were assessed using Kaplan–Meier/Cox regression, time‐dependent area under the curve, Brier score, net reclassification improvement, and integrated discrimination improvement. Overall, 28,882 LNs were evaluated; patients were classified as LNRG 0–4 in 385 (39.9%), 150 (15.5%), 26 (2.7%), 141 (14.6%), and 263 (27.3%), respectively. LNRG independently predicted disease‐free and overall survival, with Grades 1–2 conferring the most favorable outcomes and Grade 4 the poorest. A random survival forest model incorporating LNRG, tumor regression grade, ypAJCC stage, and perineural invasion predicted 2‐year disease‐free survival in training and external validation cohorts. LNRG is a novel, independent prognostic indicator after NCIT.Keywords
Funding Information
- National Natural Science Foundation of China (82272733)
- National Natural Science Foundation of China (82273083)
- National Natural Science Foundation of China (82503646)
This publication has 24 references indexed in Scilit:
- The role of pathological response in predicting the benefit of adjuvant therapy after neoadjuvant chemoimmunotherapy in patients with esophageal cancerEuropean Journal of Surgical Oncology, 2025
- Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell CarcinomaJAMA Surgery, 2025
- A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trialCancer Cell, 2024
- Predicting outcomes in esophageal adenocarcinoma following neoadjuvant chemoradiation: Interactions between tumor response and survivalThe Journal of Thoracic and Cardiovascular Surgery, 2023
- Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodesCell, 2023
- The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodesCell, 2022
- Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinomaBritish Journal of Surgery, 2018
- The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targetsCancer Treatment Reviews, 2014
- Perineural invasion in cancerCancer, 2009
- Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapyCancer, 2003